Literature DB >> 29481536

Murine-specific Internal Dosimetry for Preclinical Investigations of Imaging and Therapeutic Agents.

Bryan Bednarz, Joseph Grudzinski, Ian Marsh, Abby Besemer, Dana Baiu, Jamey Weichert, Mario Otto.   

Abstract

There is a growing need to estimate the absorbed dose to small animals from preclinical investigations involving diagnostic and therapeutic radiopharmaceuticals. This paper introduces a Monte Carlo-based dosimetry platform called RAPID, which is capable of calculating murine-specific three-dimensional (3D) dose distributions. A comparison is performed between absorbed doses calculated with RAPID and absorbed doses calculated in a commonly used reference mouse phantom called MOBY. Four test mice containing different xenografts underwent serial PET/CT imaging using a novel diagnostic therapy (theranostic) agent NM404, which can be labeled with I for imaging or I for therapy. Using the PET/CT data, 3D dose distributions from I-NM404 were calculated in the mice using RAPID. Mean organ doses in these four test mice were compared to mean organ doses derived by using two previously published I S-values datasets in MOBY. In addition, mean tumor doses calculated in RAPID were compared to mean organ doses derived from unit density spheres. Large differences were identified between mean organ doses calculated in the test mice using RAPID and those derived in the MOBY phantom. Mean absorbed dose percent errors in organs ranged between 0.3% and 333%. Overall, mass scaling improved agreement between MOBY phantom calculations and RAPID, where percent errors were all less than 26%, with the exception of the lung in which percent errors reached values of 48%. Percent errors in mean tumor doses in the test mice and unit density spheres were less pronounced but still ranged between 8% and 23%. This work demonstrates the limitations of using pre-computed S-values in computational phantoms to predict organ doses in small animals from theranostic procedures. RAPID can generate accurate 3D dose distributions in small animals and in turn offer much greater insight on the ability of a given theranostic agent to image and treat diseases.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29481536      PMCID: PMC5831541          DOI: 10.1097/HP.0000000000000789

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   1.316


  32 in total

1.  A preclinical simulated dataset of S-values and investigation of the impact of rescaled organ masses using the MOBY phantom.

Authors:  Theodora Kostou; Panagiotis Papadimitroulas; George Loudos; George C Kagadis
Journal:  Phys Med Biol       Date:  2016-03-01       Impact factor: 3.609

2.  Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy.

Authors:  Jamey P Weichert; Paul A Clark; Irawati K Kandela; Abram M Vaccaro; William Clarke; Marc A Longino; Anatoly N Pinchuk; Mohammed Farhoud; Kyle I Swanson; John M Floberg; Joseph Grudzinski; Benjamin Titz; Anne M Traynor; Hong-En Chen; Lance T Hall; Christopher J Pazoles; Perry J Pickhardt; John S Kuo
Journal:  Sci Transl Med       Date:  2014-06-11       Impact factor: 17.956

3.  A mouse model for calculating the absorbed beta-particle dose from (131)I- and (90)Y-labeled immunoconjugates, including a method for dealing with heterogeneity in kidney and tumor.

Authors:  A A Flynn; A J Green; R B Pedley; G M Boxer; R Boden; R H Begent
Journal:  Radiat Res       Date:  2001-07       Impact factor: 2.841

4.  Concurrent Monte Carlo transport and fluence optimization with fluence adjusting scalable transport Monte Carlo.

Authors:  Y M Yang; M Svatos; C Zankowski; B Bednarz
Journal:  Med Phys       Date:  2016-06       Impact factor: 4.071

5.  OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine.

Authors:  Michael G Stabin; Richard B Sparks; Eric Crowe
Journal:  J Nucl Med       Date:  2005-06       Impact factor: 10.057

6.  Evaluation of parameters influencing S values in mouse dosimetry.

Authors:  Cecilia Hindorf; Michael Ljungberg; Sven-Erik Strand
Journal:  J Nucl Med       Date:  2004-11       Impact factor: 10.057

7.  Monte Carlo-based evaluation of S-values in mouse models for positron-emitting radionuclides.

Authors:  Tianwu Xie; Habib Zaidi
Journal:  Phys Med Biol       Date:  2012-12-10       Impact factor: 3.609

8.  The accuracy of EGSnrc, Geant4 and PENELOPE Monte Carlo systems for the simulation of electron scatter in external beam radiotherapy.

Authors:  Bruce A Faddegon; Iwan Kawrakow; Yuri Kubyshin; Joseph Perl; Josep Sempau; Laszlo Urban
Journal:  Phys Med Biol       Date:  2009-09-24       Impact factor: 3.609

9.  A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates.

Authors:  T E Hui; D R Fisher; J A Kuhn; L E Williams; C Nourigat; C C Badger; B G Beatty; J D Beatty
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

10.  Monte Carlo simulations of absorbed dose in a mouse phantom from 18-fluorine compounds.

Authors:  Richard Taschereau; Arion F Chatziioannou
Journal:  Med Phys       Date:  2007-03       Impact factor: 4.071

View more
  7 in total

1.  PARaDIM: A PHITS-Based Monte Carlo Tool for Internal Dosimetry with Tetrahedral Mesh Computational Phantoms.

Authors:  Lukas M Carter; Troy M Crawford; Tatsuhiko Sato; Takuya Furuta; Chansoo Choi; Chan Hyeong Kim; Justin L Brown; Wesley E Bolch; Pat B Zanzonico; Jason S Lewis
Journal:  J Nucl Med       Date:  2019-06-14       Impact factor: 10.057

2.  Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.

Authors:  Paul A Clark; Raghava N Sriramaneni; Amber M Bates; Won Jong Jin; Justin C Jagodinsky; Reinier Hernandez; Trang Le; Justin J Jeffery; Ian R Marsh; Joseph J Grudzinski; Eduardo Aluicio-Sarduy; Todd E Barnhart; Bryce R Anderson; Ishan Chakravarty; Ian S Arthur; KyungMann Kim; Jonathan W Engle; Bryan P Bednarz; Jamey P Weichert; Zachary S Morris
Journal:  Radiat Res       Date:  2021-06-01       Impact factor: 2.841

Review 3.  Preclinical Voxel-Based Dosimetry in Theranostics: a Review.

Authors:  Arun Gupta; Min Sun Lee; Joong Hyun Kim; Dong Soo Lee; Jae Sung Lee
Journal:  Nucl Med Mol Imaging       Date:  2020-04-19

4.  Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy.

Authors:  Justin C Jagodinsky; Won Jong Jin; Amber M Bates; Reinier Hernandez; Joseph J Grudzinski; Ian R Marsh; Ishan Chakravarty; Ian S Arthur; Luke M Zangl; Ryan J Brown; Erin J Nystuen; Sarah E Emma; Caroline Kerr; Peter M Carlson; Raghava N Sriramaneni; Jonathan W Engle; Eduardo Aluicio-Sarduy; Todd E Barnhart; Trang Le; KyungMann Kim; Bryan P Bednarz; Jamey P Weichert; Ravi B Patel; Zachary S Morris
Journal:  Theranostics       Date:  2021-04-15       Impact factor: 11.600

5.  Comparison of absorbed dose extrapolation methods for mouse-to-human translation of radiolabelled macromolecules.

Authors:  Francesco Cicone; David Viertl; Thibaut Denoël; Michael G Stabin; John O Prior; Silvano Gnesin
Journal:  EJNMMI Res       Date:  2022-04-11       Impact factor: 3.138

6.  Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting.

Authors:  Kara Magee; Ian R Marsh; Michelle M Turek; Joseph Grudzinski; Eduardo Aluicio-Sarduy; Jonathan W Engle; Ilene D Kurzman; Cindy L Zuleger; Elizabeth A Oseid; Christine Jaskowiak; Mark R Albertini; Karla Esbona; Bryan Bednarz; Paul M Sondel; Jamey P Weichert; Zachary S Morris; Reinier Hernandez; David M Vail
Journal:  PLoS One       Date:  2021-08-12       Impact factor: 3.752

7.  Antitumor efficacy of 90Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors.

Authors:  Hemanth K Potluri; Carolina A Ferreira; Joseph Grudzinski; Christopher Massey; Eduardo Aluicio-Sarduy; Jonathan W Engle; Ohyun Kwon; Ian R Marsh; Bryan P Bednarz; Reinier Hernandez; Jamey P Weichert; Douglas G McNeel
Journal:  J Immunother Cancer       Date:  2022-08       Impact factor: 12.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.